NCT00722722View on ClinicalTrials.gov

The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Kidney Transplantation
Interventions
DRUG

Bortezomib

Velcade given in four-dose cycles intravenously (through a vein).

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER